In the development stage Stay tuned

Canine Atopic Dermatitis (CAD), also known as atopic dermatitis, is a chronic, refractory, relapsing, inflammatory skin disease that presents as moderate to severe in more than half of the affected dogs that present to the hospital; the main symptoms in these dogs are a large rash and intolerable, intense itching.

About 10% of dogs are susceptible to this disease, with a higher incidence in Dalmatians. Dogs usually show signs of atopic dermatitis between the ages of 3 months and 6 years.

The main ones include.

• redness of the skin, *
• rash, *
• itching.
• Hair loss, *
• skin infections, *
• crusting, *
• discoloration, *
• frequent licking and biting, etc.

Symptoms may be mild at first, but they usually worsen over time as the skin becomes more sensitive. These symptoms may be generalized and spread throughout the body, or they may be localized and usually appear on the ears, face, feet, armpits, and legs.

Dogs with moderately severe or severe CAD may develop a large rash and unbearable intense itching with a strong odor that severely affects the quality of life and makes them very vulnerable to owner abandonment.

Currently, antihistamines, corticosteroids, and cyclosporine are commonly used clinically to alleviate the symptoms of canine atopic dermatitis, but strong immune agents are often used to treat CAD along with many serious side effects, including oral hyperplasia, anemia, decreased immunity, and tumors.

MT-5241 is a monoclonal antibody drug targeting IL-4R that binds IL 4Rα, a receptor module common to IL 4 and IL-13, and blocks both IL-4 and IL-13 signaling, providing excellent control of a variety of type 2 immune-related inflammatory diseases.

Currently, MUTIAN has conducted several clinical trials for MT-5241 in adult patients with chronic spontaneous urticaria, moderate to severe atopic dermatitis, moderate to severe COPD, asthma, nodular itchy rash, rheumatoid arthritis and multiple indications for other inflammatory diseases.